logo

For the Inventor, By the Inventor

Cincinnati, OH, United States of America

Aerpio Therapeutics, Inc.


USPTO Granted Patents = 35

% Expired Patents = 40.0



Forward Citations = 787

Loading Chart...
Loading Chart...

19 inventors (with patents filed for the assignee):

goldMedal Robert A Shalwitz (19 out of 33 patents)

silverMedal Kevin Gene Peters (14 out of 35 patents)

bronzeMedal Jeffrey Lyle Gray (11 out of 23 patents)

4.  Cynthia Monesa Clark (11 out of 16 patents)

5.  Ryan Matthew Nichols (11 out of 16 patents)

6.  Matthew B Maier (11 out of 16 patents)

7.  Kande K D Amarasinghe (11 out of 16 patents)

8.  Joseph H Gardner (9 out of 17 patents)

9.  John M Janusz (2 out of 37 patents)

10.  Alexander Smith (1 out of 17 patents)

11.  Boris Gorin (1 out of 32 patents)

12.  Jan Oudenes (1 out of 18 patents)

13.  Craig Edward Dixon (1 out of 10 patents)

14.  Michael Allen Flynn (1 out of 6 patents)

15.  James Densmore Copp (1 out of 17 patents)


Core Competencies:
Prolyl Hydroxylase Inhibitors
Ocular Disease
Cancer Metastasis
HPTP-beta
Immunotherapy
Hypoxia Inducible Factor
Vascular Leak Syndrome
Antibodies
Compositions
Methods
Formulations

35 patents:

1. 10562854 - Prolyl hydroxylase inhibitors (2020-02-18),
2. 10329357 - Treatment of ocular disease (2019-06-25),
3. 10253094 - Antibodies that target human protein tyrosine phosphatase-beta (HPTP-beta) and methods of use thereof to treat ocular conditions (2019-04-09),
4. 10220048 - Compositions and methods for treating ocular diseases (2019-03-05),
5. 10150811 - Methods for treating vascular leak syndrome and cancer (2018-12-11),
6. 9994560 - HPTP-β inhibitors (2018-06-12),
7. 9949956 - Compounds, compositions, and methods for preventing metastasis of cancer cells (2018-04-24),
8. 9926367 - Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof (2018-03-27),
9. RE46592 - Human protein tyrosine phosphatase inhibitors and methods of use (2017-10-30),
10. 9795594 - Human protein tyrosine phosphatase inhibitors and methods of use (2017-10-24),
11. 9540326 - Prolyl hydroxylase inhibitors (2017-01-10),
12. 9539245 - Combination of immunotherapies with activators of Tie-2 (2017-01-10),
13. 9440963 - Compositions, formulations and methods for treating ocular diseases (2016-09-13),
14. 9388135 - Process for preparing N-benzyl-3-hydroxy-4-substituted-pyridin-2-(1H)-ones (2016-07-12),
15. 9284285 - Human protein tyrosine phosphatase inhibitors and methods of use (2016-03-15),
Company Overview
Aerpio Therapeutics, Inc. is a biopharmaceutical company based in Cincinnati, Ohio, focused on developing innovative therapies for ocular diseases and other conditions. The company specializes in advancing treatments that target the underlying mechanisms of diseases, particularly those related to vascular health and angiogenesis. Aerpio's research leverages cutting-edge science to create solutions aimed at improving patient outcomes in areas where current therapies are limited or ineffective.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

35 Patents

#36 in Cincinnati, OH

#427 in Ohio

#9,756 in US

#19,181 in the World

Cincinnati, OH (US)
Cincinnati, OH, United States of America

Aerpio Therapeutics, Inc.

Forward Citations = 787

19 inventors:

goldMedal Robert A Shalwitz (19 out of 33 patents)

silverMedal Kevin Gene Peters (14 out of 35 patents)

bronzeMedal Jeffrey Lyle Gray (11 out of 23 patents)

4.  Cynthia Monesa Clark (11 out of 16 patents)

5.  Ryan Matthew Nichols (11 out of 16 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Aerpio Therapeutics, Inc.. Retrieved from https://idiyas.com/company/aerpio-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…